Clinically Driven Diagnostic Antifungal Approach in Neutropenic Patients: A Prospective Feasibility Study
- 1 February 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (4), 667-674
- https://doi.org/10.1200/jco.2009.21.8032
Abstract
Purpose Preemptive strategies in neutropenic patients based on serum galactomannan (GM) –guided triggering of diagnostic work-up may be time-consuming and expensive when applied to the entire population. We have assessed the feasibility of a clinically driven diagnostic strategy without GM screening. Patients and Methods Patients with neutropenic fever underwent a baseline diagnostic work-up (BDWU; three blood cultures and other examinations as indicated). An intensive diagnostic work-up (IDWU; GM for 3 days, chest computed tomography and other examinations as indicated) was reserved for patients with 4 days of persisting or relapsing fever or with other clinical findings possibly related to an invasive fungal diseaser (IFD). Antifungal therapy was administered to patients diagnosed with IFD and empirically (negative IDWU) only to those with persisting neutropenic fever and worsening clinical conditions. Results Of 220 neutropenia episodes, fever occurred in 159 cases and recurred in 28 cases. Overall, 49 IFDs were diagnosed (two by BDWU and 47 by IDWU) during 48 episodes (21.8%). Diagnostic-driven therapy was administered to 48 patients with IFDs; one patient with zygomycosis died without treatment. Only one patient received empirical therapy. IDWU was required in 40% of neutropenia episodes, and only 1.4 mean blood samples per neutropenia episode were tested for GM. Our strategy allowed a 43% reduction in antifungal treatments compared with a standard empirical approach. At 3-month follow-up, 63% of patients with IFD survived, and no undetected IFDs were found. Conclusion A clinically driven diagnostic approach in selected neutropenia episodes offered effective antifungal control and reduced the exposure to unnecessary antifungal treatment.Keywords
This publication has 23 references indexed in Scilit:
- New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patientsBest Practice & Research Clinical Haematology, 2007
- Prevention and Early Treatment of Invasive Fungal Infection in Patients with Cancer and Neutropenia and in Stem Cell Transplant Recipients in the Era of Newer Broad-Spectrum Antifungal Agents and Diagnostic AdjunctsClinical Infectious Diseases, 2007
- Invasive AspergillosisDrugs, 2007
- Antifungal therapy in patients with hematological malignancies: how to avoid overtreatment?European Journal of Haematology, 2006
- Antifungal therapy in febrile neutropenic patients: review of treatment choices and strategies for aspergillar infectionSupportive Care in Cancer, 2006
- Galactomannan and Computed Tomography-Based Preemptive Antifungal Therapy in Neutropenic Patients at High Risk for Invasive Fungal Infection: A Prospective Feasibility StudyClinical Infectious Diseases, 2005
- Perspectives for the management of febrile neutropenic patients with cancer in the 21st centuryCancer, 2005
- Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatmentThe Lancet Oncology, 2003
- 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with CancerClinical Infectious Diseases, 2002
- Persistent Fever in Patients with NeutropeniaNew England Journal of Medicine, 2002